ADP report reveals unexpected job losses, intensified by the ongoing government shutdown and delayed BLS data.
S&P Global Ratings report highlights risks of low profitability and credit shocks in the Chinese banking sector as Beijing prioritizes economic growth.
Phase IV trial data reveals the drug helps patients achieve LDL-C goals with reduced muscle pain, bolstering its market position.
Zilebesiran, a twice-yearly injection, will be tested in 11,000 high-risk patients following promising mid-stage results.
New analyses from the REDUCE-IT trial show a 9% reduction in hospitalizations, bolstering the drug's profile amid ongoing generic competition.
Long-term study data presented at a major cardiology conference reinforces the drug's potential in treating a rare heart condition.
Financing deal carries risk of 46% equity dilution, coupled with a 1-for-7 reverse stock split to maintain Nasdaq listing.
Aficamten proves superior to metoprolol for hypertrophic cardiomyopathy, positioning the drug for a potential shift in treatment standards.